Neko Health: Preventive Checkups as a Business

Operates its own clinics in Stockholm, London and other locations, offering a 10–15-minute full-body scan with 70+ sensors and millions of data points plus a doctor consultation, charging per visit and encouraging annual repeat purchases.

Consumers will pay out-of-pocket for preventive checkups. Build own hardware, software, clinics; use 10-15 minute scans to drive annual repeat purchases.

After 2018, Daniel Ek invested about €30M upfront through Prima Materia; in July 2023, a $65M Series A (led by Lakestar, with Atomico, General Catalyst, and Prima Materia); in January 2025, a $260M Series B (led by Lightspeed, valued at $1.8B); in July 2026, a $700M Series C (led by Lightspeed and O.G. Venture Partners).

In 2018, Daniel Ek saw Hjalmar Nilsonne's post about the healthcare market on Twitter and contacted him by direct message; neither had a healthcare background (Nilsonne had previously worked in climate tech), and their conversation produced the idea of preventive healthcare plus vertical integration. The team spent six years developing its own scanning hardware and software and building its own clinics, opening the first store in Stockholm in February 2023; appointment slots sold out within hours of opening.

In July 2023, completed a $65M Series A (led by Lakestar, with Atomico, General Catalyst, and Prima Materia participating); in 2024, opened the second store in London, by which time Stockholm had completed about 3,000 scans and Sweden's waitlist had about 20,000 people. In January 2025, completed a $260M Series B, led by Lightspeed, valued at $1.8B, with cumulative scans of 10,000 and a global waitlist of more than 100,000 people, and 80% of members prepaid for the next year's scan on the spot.

In July 2026, raised another $700M Series C (led by Lightspeed and O.G. Venture Partners), with cumulative financing exceeding $1B; already operating in the United Kingdom and Sweden, preparing for its first U.S. clinic in New York; as of July 2026, cumulative scans exceeded 100,000 people and waitlist and appointments exceeded 350,000 people. The company is still expanding rapidly.

Demand validated: slots sold out on opening day; 80% prepaid for next year.

Vertical integration creates data and experience moat.

Investors see platform potential: from $65M Series A to $1.8B valuation.

Risk: scans don't equal improved outcomes; self-pay limits access.

Turn prevention into a product: vertically integrate hardware, software, clinics. Prove repeat purchases (80% prepay) to attract capital. But clinical evidence and regulatory trust are essential.

As of 2026-09-01, Neko Health operates in Stockholm and London, preparing for New York. Completed 100,000+ scans, waitlist 350,000+. After $700M Series C, expands clinics and R&D. Competitors like Zoi, Aware, Midjourney emerge. Next: prove long-term clinical and commercial value.